| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(98)10166-6 |
| P698 | PubMed publication ID | 10440304 |
| P2093 | author name string | A Elbaz | |
| D Caparros-Lefebvre | |||
| P2860 | cites work | Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology | Q28278604 |
| Screening of medicinal plants from Suriname for 5-HT(1A) ligands: Bioactive isoquinoline alkaloids from the fruit of Annona muricata | Q29354115 | ||
| Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases | Q29614910 | ||
| Progressive supranuclear palsy as the sole manifestation of systemic Whipple's disease treated with pefloxacine | Q33590236 | ||
| 1‐Benzyl‐1,2,3,4‐Tetrahydroisoquinoline as a Parkinsonism‐Inducing Agent: A Novel Endogenous Amine in Mouse Brain and Parkinsonian CSF | Q34298649 | ||
| Parkinsonism-dementia complex, an endemic disease on the island of Guam. II. Pathological features | Q34540135 | ||
| Prevalence and natural history of progressive supranuclear palsy | Q34687903 | ||
| A cohort study of amyotrophic lateral sclerosis and parkinsonism-dementia on Guam and Rota | Q34692379 | ||
| Amyotrophic lateral sclerosis and parkinsonism-dementia on Guam: a 30-year evaluation of clinical and neuropathologic trends | Q34694646 | ||
| Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease | Q36900834 | ||
| Tetrahydropapaveroline and its derivatives inhibit dopamine uptake through dopamine transporter expressed in HEK293 cells | Q41046092 | ||
| Guam amyotrophic lateral sclerosis-parkinsonism-dementia linked to a plant excitant neurotoxin | Q41458956 | ||
| Isoquinoline neurotoxins in the brain and Parkinson's disease | Q41634669 | ||
| Cytotoxicity of isoquinoline alkaloids and their N-oxides | Q42198479 | ||
| Isoquinoline derivatives isolated from the fruit of Annona muricata as 5-HTergic 5-HT1A receptor agonists in rats: unexploited antidepressive (lead) products. | Q42833941 | ||
| Intracerebral microdialysis neurotoxicity studies of quinoline and isoquinoline derivatives related to MPTP/MPP+. | Q46291521 | ||
| Familial nature and continuing morbidity of the amyotrophic lateral sclerosis-parkinsonism dementia complex of Guam | Q47332369 | ||
| Synthesis and dopamine receptor selectivity of the benzyltetrahydroisoquinoline, (R)-(+)-nor-roefractine | Q47918192 | ||
| Novel endogenous 1,2,3,4-tetrahydroisoquinoline derivatives: uptake by dopamine transporter and activity to induce parkinsonism | Q48547042 | ||
| Chronic administration of 1-benzyl-1,2,3,4-tetrahydroisoquinoline, an endogenous amine in the brain, induces parkinsonism in a primate | Q48891332 | ||
| [Alkaloids of Annonaceae. XXIX. Alkaloids of Annona muricata]. | Q52539611 | ||
| Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). | Q52888984 | ||
| The Biosynthesis of Opium Alkaloids. Reticuline as the Benzyltetrahydroisoquinoline Precursor of Thebaine in Biosynthesis with Carbon-14 Dioxide* | Q55062199 | ||
| Amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam: quantitative neuropathology, immunohistochemical analysis of neuronal vulnerability, and comparison with related neurodegenerative disorders | Q60308713 | ||
| Accuracy of the Clinical Diagnoses of Lewy Body Disease, Parkinson Disease, and Dementia With Lewy Bodies | Q60932741 | ||
| Amyotrophic lateral sclerosis and parkinsonism-dementia complex of Guam. Neurological reevaluation. | Q67219404 | ||
| Interaction of bovine glutamate dehydrogenase with isoquinoline alkaloids | Q71677602 | ||
| Neurodegenerative 'overlap' syndrome: Clinical and pathological features of Parkinson's disease, motor neuron disease, and Alzheimer's disease | Q81553957 | ||
| P433 | issue | 9175 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Caribbean | Q664609 |
| Parkinson's disease | Q11085 | ||
| parkinsonian syndrome | Q1531991 | ||
| P304 | page(s) | 281-286 | |
| P577 | publication date | 1999-07-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study. Caribbean Parkinsonism Study Group | |
| P478 | volume | 354 |
| Q64854001 | Q64854001 |
| Q39197777 | A Review on Annona squamosa L.: Phytochemicals and Biological Activities |
| Q36196941 | A geographical cluster of progressive supranuclear palsy in northern France |
| Q33855498 | A trawl through the current nutrition literature |
| Q38667045 | Acetogenins from Annonaceae. |
| Q35163794 | Aged monkeys as a partial model for Parkinson's disease |
| Q34802001 | Amine-related neurotoxins in Parkinson's disease: past, present, and future |
| Q26800000 | Annona muricata (Annonaceae): A Review of Its Traditional Uses, Isolated Acetogenins and Biological Activities |
| Q48103083 | Annonacin, a natural mitochondrial complex I inhibitor, causes tau pathology in cultured neurons |
| Q34250977 | Annonamine, a new aporphine alkaloid from the leaves of Annona muricata |
| Q33816857 | Atypical parkinsonism in Afro-Caribbean and Indian origin immigrants to the UK. |
| Q34575656 | Atypical parkinsonism in Guadeloupe: a common risk factor for two closely related phenotypes? |
| Q64854013 | Atypical parkinsonism in the French West Indies |
| Q33954091 | Basal ganglia neurotoxins |
| Q62583228 | Cardiotoxicity of acetogenins from Persea americana occurs through the mitochondrial permeability transition pore and caspase-dependent apoptosis pathways |
| Q82029198 | Chapter 13 Amyotrophic lateral sclerosis |
| Q38749513 | Chronic consumption of Annona muricata juice triggers and aggravates cerebral tau phosphorylation in wild-type and MAPT transgenic mice. |
| Q42436464 | Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats |
| Q46328664 | Clinical effects of chemical exposures on mitochondrial function. |
| Q38223118 | Clinical trials: past, current, and future for atypical Parkinsonian syndromes |
| Q60950334 | Dietary Variations in a Multiethnic Parkinson's Disease Cohort and Possible Influences on Nonmotor Aspects: A Cross-Sectional Multicentre Study |
| Q45076842 | Experimental evidence for a toxic etiology of tropical parkinsonism |
| Q34238077 | Experimental models of Parkinson's disease |
| Q55512594 | Exploring the Leaves of Annona muricata L. as a Source of Potential Anti-inflammatory and Anticancer Agents. |
| Q33183514 | Guadeloupean parkinsonism: a cluster of progressive supranuclear palsy-like tauopathy |
| Q34571137 | Is atypical parkinsonism in the Caribbean caused by the consumption of Annonacae? |
| Q26824755 | Is neurodegenerative disease a long-latency response to early-life genotoxin exposure? |
| Q33520665 | MALDI-TOF MS profiling of annonaceous acetogenins in Annona muricata products for human consumption |
| Q37882597 | Milestones in atypical and secondary Parkinsonisms |
| Q47147993 | Mitochondria: A Common Target for Genetic Mutations and Environmental Toxicants in Parkinson's Disease |
| Q35412397 | Mitochondrial Dysfunction and α-Synuclein Synaptic Pathology in Parkinson's Disease: Who's on First? |
| Q38539848 | Mitochondrial dysfunction and Parkinson disease: a Parkin-AMPK alliance in neuroprotection |
| Q37906364 | Mitochondrial dysfunction as a therapeutic target in progressive supranuclear palsy |
| Q38021865 | Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences |
| Q28298685 | Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells |
| Q41867776 | Movement Disorders Among Adult Neurological Outpatients Evaluated over 20 Years in Guayaquil, Ecuador |
| Q38430500 | Multiple-system atrophy in long-term professional painter: a case report |
| Q36994301 | Neurodegenerative diseases: neurotoxins as sufficient etiologic agents? |
| Q46664339 | Neurotoxicity of Dietary Supplements from Annonaceae Species. |
| Q44328307 | Neurotoxicity of an endogenous brain amine, 1-benzyl-1,2,3,4-tetrahydroisoquinoline, in organotypic slice co-culture of mesencephalon and striatum |
| Q44537838 | Occurrence of atypical parkinsonism in Indians and Caucasians |
| Q43629642 | Parkinsonism after glycine-derivate exposure |
| Q34600121 | Piericidin A aggravates Tau pathology in P301S transgenic mice |
| Q34802021 | Potential neurotoxic "agents provocateurs" in Parkinson's disease |
| Q34566352 | Progress in the pathogenesis of amyotrophic lateral sclerosis |
| Q57306343 | Progressive Supranuclear Palsy and Corticobasal Degeneration |
| Q38806105 | Progressive supranuclear palsy (PSP): Richardson syndrome and other PSP variants |
| Q34826125 | Progressive supranuclear palsy and its relation to pacific foci of the parkinsonism-dementia complex and Guadeloupean parkinsonism |
| Q29999209 | Progressive supranuclear palsy in the molecular age |
| Q34558624 | Progressive supranuclear palsy: clinical features, pathophysiology and management |
| Q30810295 | Progressive supranuclear palsy: where are we now? |
| Q34581908 | REM sleep behavior disorder in patients with guadeloupean parkinsonism, a tauopathy. |
| Q37753509 | Rational therapeutic approaches to progressive supranuclear palsy |
| Q57089159 | Research goals in progressive supranuclear palsy |
| Q46728310 | Risk factors of multiple system atrophy: a case-control study in French patients |
| Q34120276 | Selective dopaminergic neurotoxicity of isoquinoline derivatives related to Parkinson's disease: studies using heterologous expression systems of the dopamine transporter |
| Q46606421 | Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial |
| Q36049419 | Synergistic interactions among flavonoids and acetogenins in Graviola (Annona muricata) leaves confer protection against prostate cancer |
| Q33761048 | Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. |
| Q44489337 | The epidemiology of progressive supranuclear palsy |
| Q39295606 | The epidemiology of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). |
| Q33972895 | The mitochondrial complex I inhibitor annonacin is toxic to mesencephalic dopaminergic neurons by impairment of energy metabolism. |
| Q46747405 | The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy |
| Q39160051 | Toxicity of Annonaceae for dopaminergic neurons: potential role in atypical parkinsonism in Guadeloupe. |
| Q35540189 | Update on epidemiological aspects of progressive supranuclear palsy |
| Q89805038 | Xenobiotics, Trace Metals and Genetics in the Pathogenesis of Tauopathies |
Search more.